PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield
New Jersey
07080-2449
United States
Website: http://www.ptcbio.com/
460 articles with PTC Therapeutics, Inc.
-
PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
1/14/2021
- New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 -
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 13, 2021
1/13/2021
PTC Therapeutics, Inc. announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 10 new employees.
-
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
1/11/2021
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan Healthcare Conference today, Monday, Jan. 11 at 7:30 a.m. EST.
-
PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11 th at 7:30 a.m. EST . The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC The
-
PTC Therapeutics to Host Translarna™ Deep Dive Webinar
12/9/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET . The Translarna Deep Dive will provide an overview of results from the clinical and real-world data generated to date for the treatment of nonsense mutation Duchenne muscula
-
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
-
PTC Therapeutics Reports Grants Under Nasdaq Listing Rule 5635(c)(4)
12/4/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of 41,955 shares of its common stock and 20,735 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 47 new employe
-
PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
12/4/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD).
-
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
11/30/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA).
-
PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
11/19/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1 st at 11:45 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of
-
PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications
11/18/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment of leiomyosarcoma (LMS), a rare type of cancer that affects smooth muscle tissue.
-
PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
11/17/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing platform and is being developed for the treatment of
-
PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases
11/16/2020
- AADC deficiency associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy - - Patient and caregiver quality of life study reveals real-life impact of nonsense mutation Duchenne muscular dystrophy and reinforces value of treatment -
-
PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
10/29/2020
- Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch - - Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase - - Initiated registration-directed trial with vatiquinone (PTC743) for mitochondrial epilepsy - ,
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 28, 2020
10/28/2020
PTC Therapeutics, Inc. announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 18 new employees.
-
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
10/28/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Credit Suisse 29 th Annual Virtual Healthcare Conference Wednesday, November 11 th at 9:30 a.m. ET Barclays Virtual Gene Editing & Gene Therapy Summit Monday, November 16 th
-
PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts
10/22/2020
- Massachusetts signs proclamation declaring Oct.23 as AADC Deficiency Awareness Day - - PTC hosts Facebook Live event featuring leaders from AADC Family Network, MassBio, and Boston Children's Hospital -
-
Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy
10/21/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance Agency (ANVISA) for the treatment of spinal muscular atrophy (SMA).
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
9/28/2020
PTC Therapeutics, Inc. announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™ continued to improve and achieve motor milestones.